ENVISION: UGN-102 Shows Promise as Chemoablative Therapy for LG-IR-NMIBC

Sia Daneshmand, MD, reviews the results of the ENVISION trial, which evaluates chemoablation using a novel reverse gel formulation of mitomycin for patients with intermediate-risk bladder cancer. The trial achieved a 79% complete response rate at three months, with 80% of responders maintaining durability at one year. Dr. Daneshmand highlights the benefits of avoiding TURBT and the potential to reduce recurrent operating room visits, especially for older patients or those on anticoagulation.